Danske Bank A S Makes New $10.16 Million Investment in Illumina, Inc. $ILMN

Danske Bank A S bought a new position in Illumina, Inc. (NASDAQ:ILMN) in the 2nd quarter, Holdings Channel reports. The firm bought 57,809 shares of the life sciences company’s stock, valued at approximately $10,165,000.

Other hedge funds have also made changes to their positions in the company. Empowered Funds LLC grew its position in shares of Illumina by 113.7% in the 1st quarter. Empowered Funds LLC now owns 9,284 shares of the life sciences company’s stock worth $737,000 after buying an additional 4,940 shares during the last quarter. Sivia Capital Partners LLC purchased a new stake in Illumina during the second quarter valued at approximately $621,000. CW Advisors LLC purchased a new stake in Illumina during the second quarter valued at approximately $275,000. Marshall Wace LLP boosted its stake in Illumina by 49.0% in the second quarter. Marshall Wace LLP now owns 59,645 shares of the life sciences company’s stock valued at $5,691,000 after acquiring an additional 19,618 shares in the last quarter. Finally, Cresset Asset Management LLC boosted its stake in Illumina by 30.9% in the second quarter. Cresset Asset Management LLC now owns 7,404 shares of the life sciences company’s stock valued at $706,000 after acquiring an additional 1,748 shares in the last quarter. 89.42% of the stock is currently owned by hedge funds and other institutional investors.

Illumina Price Performance

Shares of ILMN opened at $219.40 on Friday. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.80 and a quick ratio of 1.40. The company’s fifty day moving average price is $188.01 and its 200-day moving average price is $152.44. Illumina, Inc. has a 1-year low of $88.00 and a 1-year high of $220.43. The firm has a market capitalization of $33.13 billion, a PE ratio of 40.93, a price-to-earnings-growth ratio of 3.00 and a beta of 1.45.

Illumina (NASDAQ:ILMN) last issued its earnings results on Thursday, July 30th. The life sciences company reported $1.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.23 by $0.08. The company had revenue of $1.16 billion during the quarter, compared to analyst estimates of $1.13 billion. Illumina had a return on equity of 29.84% and a net margin of 18.36%.The firm’s quarterly revenue was up 9.4% on a year-over-year basis. During the same quarter last year, the business posted $1.19 EPS. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. On average, equities research analysts predict that Illumina, Inc. will post 5.36 EPS for the current year.

Illumina News Summary

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Illumina’s latest quarterly results exceeded expectations, with earnings of $1.31 per share versus the $1.23 consensus estimate and revenue of $1.16 billion versus expectations of $1.13 billion. Revenue increased 9.4% year over year, while fiscal 2026 EPS guidance remains $5.30-$5.40. Illumina stock information
• Positive Sentiment: Several institutional investors increased their positions, including Marshall Wace, Cresset Asset Management and Empowered Funds. Hedge funds and other institutions collectively own approximately 89.4% of ILMN shares, indicating strong professional-investor participation.
• Neutral Sentiment: Analyst opinions remain mixed. Zacks Research upgraded the stock to “strong buy,” and Leerink Partners raised its target to $210, while Deutsche Bank downgraded the shares to “hold.” The overall consensus rating is “hold,” with an average target of $188.40—below recent trading levels. Analyst coverage of Illumina
• Negative Sentiment: Director Keith A. Meister sold 679,574 Illumina shares from August 19 through August 21 for approximately $145.6 million. The transactions reduced his ownership by roughly one-third, although he still holds about 1.41 million shares. The size and timing of the sales may raise concerns about insider conviction, even though the filings do not establish the reason for the transactions. SEC insider ownership filing
• Negative Sentiment: SVP Christensen Jakob Wedel also sold 1,033 shares under a pre-arranged Rule 10b5-1 trading plan. The smaller, planned transaction is less concerning than Meister’s sales but adds to the recent pattern of insider selling. Illumina insider trading alert

Insider Transactions at Illumina

In related news, CAO Scott D. Ericksen sold 1,500 shares of the company’s stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $150.10, for a total value of $225,150.00. Following the sale, the chief accounting officer owned 14,946 shares in the company, valued at $2,243,394.60. This represents a 9.12% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Keith A. Meister sold 457,858 shares of the stock in a transaction that occurred on Tuesday, August 4th. The stock was sold at an average price of $200.10, for a total transaction of $91,617,385.80. Following the completion of the transaction, the director owned 2,372,694 shares in the company, valued at approximately $474,776,069.40. This trade represents a 16.18% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 2,095,958 shares of company stock worth $401,720,974 over the last three months. 2.90% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

ILMN has been the topic of a number of recent analyst reports. Deutsche Bank Aktiengesellschaft downgraded Illumina to a “hold” rating in a research report on Wednesday, August 5th. Daiwa Securities Group upgraded Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 target price on the stock in a research note on Thursday, May 14th. Weiss Ratings raised Illumina from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, June 3rd. Piper Sandler reiterated an “overweight” rating and issued a $225.00 price target (up from $200.00) on shares of Illumina in a research note on Monday, August 3rd. Finally, Wall Street Zen raised Illumina from a “hold” rating to a “buy” rating in a report on Saturday, August 1st. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, six have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $188.40.

Illumina Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.